Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Iberdomide + Obinutuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Iberdomide||CC220|CC-220|CC 220||Iberdomide (CC-220) binds to the ubiquitin E3 ligase complex member Cereblon (CRBN), which may lead to increased ubiquitination and degradation of transcription factors, resulting in decreased B-cell proliferation (PMID: 29945920, PMID: 28848067, PMID: 31719682).|
|Obinutuzumab||Gazyva||R7159|afutuzumab|GA101|GA-101|RO 5072759||CD20 Antibody 17||Gazyva (obinutuzumab) is a glycoengineered anti-CD20 antibody that binds to CD20 on B-cells, resulting in increased antibody-dependent cellular cytotoxicity and induction of apoptosis, and potentially leading to decreased growth of B-cell tumors (PMID: 20194898, PMID: 21220500). Gazyva (obinutuzumab) is FDA approved in combination with Ambochlorin (chlorambucil) for chronic lymphocytic leukemia and in combination with Treanda (bendamustine) or chemotherapy for follicular lymphoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04464798||Phase I||Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab||A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas||Recruiting||USA | ITA | FRA | DEU||2|